Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy, Memory Impairment
Interventions: AZD8529, Placebo to match AZD8529; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine, Oxycodone Immediate-Release; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 85
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more

Conditions: Indigestion, Heartburn
Interventions: HLNatural, Inc. Upset Stomach Relief; Dietary Supplement
Lead sponsor: Hawthorne Effect Inc.; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Indianapolis, Indiana • Seattle, Washington • Madison, Wisconsin

Conditions: Preterm Delivery, Obstetrical Complications
Interventions: 162mg Aspirin, 81mg Aspirin; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 14 Years and older · Female only
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Vitamin D Insufficiency
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer
Interventions: BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 26 more

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Spasticity Due to Cerebral Palsy
Interventions: Zanaflex Capsules; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: El Cajon, California • Murrieta, California • Rialto, California + 14 more

Conditions: Cytomegalovirus Infection
Interventions: MBX400, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Food-drug Interaction
Interventions: Trifolium pratense; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, Arimoclomol; Drug
Lead sponsor: CytRx; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Interventions: REM-422; Drug
Lead sponsor: Remix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more

Conditions: Healthy
Interventions: IPI-145 (duvelisib), IPI-145; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Glioblastoma Multiforme, Adult
Interventions: Berubicin, Lomustine; Drug
Lead sponsor: CNS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Hearing Loss, Head and Neck Cancer
Interventions: Placebo, Atorvastatin; Other · Drug
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Multiple Sclerosis
Interventions: Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil; Other · Device · Dietary Supplement + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes Mellitus, Type 2
Interventions: GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C; Drug
Lead sponsor: GLWL Research Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Tempe, Arizona • Chula Vista, California • Miami, Florida + 1 more

Conditions: Renal Impairment
Interventions: Tasimelteon; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Search by objective public record fields.

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

A Clinical Trial of Antiplatelets in Psoriasis

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

Red Clover Botanical Dietary Supplements - Metabolism and Safety in Women

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

Study of REM-422 in Patients With AML or Higher Risk MDS

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function